

Antonio Palumbo

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3239926/publications.pdf>

Version: 2024-02-01

269
papers

34,087
citations

13098

68
h-index

3650

180
g-index

270
all docs

270
docs citations

270
times ranked

16941
citing authors

#	ARTICLE	IF	CITATIONS
1	International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. <i>Lancet Oncology, The</i> , 2014, 15, e538-e548.	10.7	3,343
2	Multiple Myeloma. <i>New England Journal of Medicine</i> , 2011, 364, 1046-1060.	27.0	2,109
3	International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma. <i>Lancet Oncology, The</i> , 2016, 17, e328-e346.	10.7	1,866
4	Bortezomib plus Melphalan and Prednisone for Initial Treatment of Multiple Myeloma. <i>New England Journal of Medicine</i> , 2008, 359, 906-917.	27.0	1,787
5	Revised International Staging System for Multiple Myeloma: A Report From International Myeloma Working Group. <i>Journal of Clinical Oncology</i> , 2015, 33, 2863-2869.	1.6	1,525
6	Daratumumab, Bortezomib, and Dexamethasone for Multiple Myeloma. <i>New England Journal of Medicine</i> , 2016, 375, 754-766.	27.0	1,246
7	Carfilzomib, Lenalidomide, and Dexamethasone for Relapsed Multiple Myeloma. <i>New England Journal of Medicine</i> , 2015, 372, 142-152.	27.0	1,144
8	Elotuzumab Therapy for Relapsed or Refractory Multiple Myeloma. <i>New England Journal of Medicine</i> , 2015, 373, 621-631.	27.0	1,139
9	Oral Ixazomib, Lenalidomide, and Dexamethasone for Multiple Myeloma. <i>New England Journal of Medicine</i> , 2016, 374, 1621-1634.	27.0	861
10	Consensus recommendations for the uniform reporting of clinical trials: report of the International Myeloma Workshop Consensus Panel 1. <i>Blood</i> , 2011, 117, 4691-4695.	1.4	849
11	Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma. <i>Leukemia</i> , 2008, 22, 414-423.	7.2	787
12	Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma: randomised controlled trial. <i>Lancet, The</i> , 2006, 367, 825-831.	13.7	775
13	Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicentre study. <i>Lancet Oncology, The</i> , 2016, 17, 27-38.	10.7	723
14	Continuous Lenalidomide Treatment for Newly Diagnosed Multiple Myeloma. <i>New England Journal of Medicine</i> , 2012, 366, 1759-1769.	27.0	692
15	Treatment of multiple myeloma with high-risk cytogenetics: a consensus of the International Myeloma Working Group. <i>Blood</i> , 2016, 127, 2955-2962.	1.4	686
16	Autologous Transplantation and Maintenance Therapy in Multiple Myeloma. <i>New England Journal of Medicine</i> , 2014, 371, 895-905.	27.0	683
17	Geriatric assessment predicts survival and toxicities in elderly myeloma patients: an International Myeloma Working Group report. <i>Blood</i> , 2015, 125, 2068-2074.	1.4	586
18	Lenalidomide Maintenance After Autologous Stem-Cell Transplantation in Newly Diagnosed Multiple Myeloma: A Meta-Analysis. <i>Journal of Clinical Oncology</i> , 2017, 35, 3279-3289.	1.6	535

#	ARTICLE	IF	CITATIONS
19	IMWG consensus on risk stratification in multiple myeloma. <i>Leukemia</i> , 2014, 28, 269-277.	7.2	500
20	Bortezomib Plus Melphalan and Prednisone Compared With Melphalan and Prednisone in Previously Untreated Multiple Myeloma: Updated Follow-Up and Impact of Subsequent Therapy in the Phase III VISTA Trial. <i>Journal of Clinical Oncology</i> , 2010, 28, 2259-2266.	1.6	403
21	Bortezomib-Melphalan-Prednisone-Thalidomide Followed by Maintenance With Bortezomib-Thalidomide Compared With Bortezomib-Melphalan-Prednisone for Initial Treatment of Multiple Myeloma: A Randomized Controlled Trial. <i>Journal of Clinical Oncology</i> , 2010, 28, 5101-5109.	1.6	400
22	Efficacy and safety of once-weekly bortezomib in multiple myeloma patients. <i>Blood</i> , 2010, 116, 4745-4753.	1.4	361
23	Bromodomain inhibitor OTX015 in patients with lymphoma or multiple myeloma: a dose-escalation, open-label, pharmacokinetic, phase 1 study. <i>Lancet Haematology</i> , 2016, 3, e196-e204.	4.6	344
24	Oral melphalan, prednisone, and thalidomide in elderly patients with multiple myeloma: updated results of a randomized controlled trial. <i>Blood</i> , 2008, 112, 3107-3114.	1.4	339
25	International Myeloma Working Group Consensus Statement for the Management, Treatment, and Supportive Care of Patients With Myeloma Not Eligible for Standard Autologous Stem-Cell Transplantation. <i>Journal of Clinical Oncology</i> , 2014, 32, 587-600.	1.6	330
26	Role of Magnetic Resonance Imaging in the Management of Patients With Multiple Myeloma: A Consensus Statement. <i>Journal of Clinical Oncology</i> , 2015, 33, 657-664.	1.6	330
27	Personalized therapy in multiple myeloma according to patient age and vulnerability: a report of the European Myeloma Network (EMN). <i>Blood</i> , 2011, 118, 4519-4529.	1.4	309
28	Thalidomide for treatment of multiple myeloma: 10 years later. <i>Blood</i> , 2008, 111, 3968-3977.	1.4	294
29	International Myeloma Working Group Recommendations for the Diagnosis and Management of Myeloma-Related Renal Impairment. <i>Journal of Clinical Oncology</i> , 2016, 34, 1544-1557.	1.6	294
30	European Myeloma Network Guidelines for the Management of Multiple Myeloma-related Complications. <i>Haematologica</i> , 2015, 100, 1254-1266.	3.5	289
31	Chemotherapy plus lenalidomide versus autologous transplantation, followed by lenalidomide plus prednisone versus lenalidomide maintenance, in patients with multiple myeloma: a randomised, multicentre, phase 3 trial. <i>Lancet Oncology</i> , 2015, 16, 1617-1629.	10.7	289
32	Consensus recommendations for risk stratification in multiple myeloma: report of the International Myeloma Workshop Consensus Panel 2. <i>Blood</i> , 2011, 117, 4696-4700.	1.4	285
33	Next-generation sequencing and real-time quantitative PCR for minimal residual disease detection in B-cell disorders. <i>Leukemia</i> , 2014, 28, 1299-1307.	7.2	257
34	Second primary malignancies with lenalidomide therapy for newly diagnosed myeloma: a meta-analysis of individual patient data. <i>Lancet Oncology</i> , 2014, 15, 333-342.	10.7	256
35	Complete response correlates with long-term progression-free and overall survival in elderly myeloma treated with novel agents: analysis of 1175 patients. <i>Blood</i> , 2011, 117, 3025-3031.	1.4	247
36	Vorinostat or placebo in combination with bortezomib in patients with multiple myeloma (VANTAGE) Tj ETQq0 0 0 ggBJ /Overlock 10 Tf	10.7	219

#	ARTICLE	IF	CITATIONS
37	Management of treatment-emergent peripheral neuropathy in multiple myeloma. <i>Leukemia</i> , 2012, 26, 595-608.	7.2	217
38	New drugs and novel mechanisms of action in multiple myeloma in 2013: a report from the International Myeloma Working Group (IMWG). <i>Leukemia</i> , 2014, 28, 525-542.	7.2	214
39	Randomized phase 2 study: elotuzumab plus bortezomib/dexamethasone vs bortezomib/dexamethasone for relapsed/refractory MM. <i>Blood</i> , 2016, 127, 2833-2840.	1.4	207
40	Management of relapsed multiple myeloma: recommendations of the International Myeloma Working Group. <i>Leukemia</i> , 2016, 30, 1005-1017.	7.2	204
41	Bortezomib-Melphalan-Prednisone-Thalidomide Followed by Maintenance With Bortezomib-Thalidomide Compared With Bortezomib-Melphalan-Prednisone for Initial Treatment of Multiple Myeloma: Updated Follow-Up and Improved Survival. <i>Journal of Clinical Oncology</i> , 2014, 32, 634-640.	1.6	198
42	Age and organ damage correlate with poor survival in myeloma patients: meta-analysis of 1435 individual patient data from 4 randomized trials. <i>Haematologica</i> , 2013, 98, 980-987.	3.5	193
43	Oral ixazomib maintenance following autologous stem cell transplantation (TOURMALINE-MM3): a double-blind, randomised, placebo-controlled phase 3 trial. <i>Lancet, The</i> , 2019, 393, 253-264.	13.7	187
44	Clinical efficacy and management of monoclonal antibodies targeting CD38 and SLAMF7 in multiple myeloma. <i>Blood</i> , 2016, 127, 681-695.	1.4	179
45	IMWG consensus on maintenance therapy in multiple myeloma. <i>Blood</i> , 2012, 119, 3003-3015.	1.4	178
46	Interpreting clinical trial data in multiple myeloma: translating findings to the real-world setting. <i>Blood Cancer Journal</i> , 2018, 8, 109.	6.2	170
47	International Myeloma Working Group recommendations for global myeloma care. <i>Leukemia</i> , 2014, 28, 981-992.	7.2	162
48	Survival and Years of Life Lost in Different Age Cohorts of Patients With Multiple Myeloma. <i>Journal of Clinical Oncology</i> , 2010, 28, 1599-1605.	1.6	142
49	Continuous Therapy Versus Fixed Duration of Therapy in Patients With Newly Diagnosed Multiple Myeloma. <i>Journal of Clinical Oncology</i> , 2015, 33, 3459-3466.	1.6	138
50	Carfilzomib, cyclophosphamide, and dexamethasone in patients with newly diagnosed multiple myeloma: a multicenter, phase 2 study. <i>Blood</i> , 2014, 124, 63-69.	1.4	126
51	18F-FDG PET/CT focal, but not osteolytic, lesions predict the progression of smoldering myeloma to active disease. <i>Leukemia</i> , 2016, 30, 417-422.	7.2	120
52	Elotuzumab plus lenalidomide/dexamethasone for relapsed or refractory multiple myeloma: <sc>ELOQUENT</sc> follow-up and <i>post-hoc</i> analyses on progression-free survival and tumour growth. <i>British Journal of Haematology</i> , 2017, 178, 896-905.	2.5	120
53	Mutational activation of N- and K-ras oncogenes in plasma cell dyscrasias. <i>Blood</i> , 1993, 81, 2708-2713.	1.4	116
54	Minimal Residual Disease Detection by Droplet Digital PCR in Multiple Myeloma, Mantle Cell Lymphoma, and Follicular Lymphoma. <i>Journal of Molecular Diagnostics</i> , 2015, 17, 652-660.	2.8	115

#	ARTICLE	IF	CITATIONS
55	Carfilzomib significantly improves the progression-free survival of high-risk patients in multiple myeloma. <i>Blood</i> , 2016, 128, 1174-1180.	1.4	110
56	Second primary malignancies in multiple myeloma: an overview and IMWG consensus. <i>Annals of Oncology</i> , 2017, 28, 228-245.	1.2	102
57	Cancer-Selective Targeting of the NF- κ B Survival Pathway with GADD45 β /MKK7 Inhibitors. <i>Cancer Cell</i> , 2014, 26, 495-508.	16.8	99
58	Phase 1/2 study of daratumumab, lenalidomide, and dexamethasone for relapsed multiple myeloma. <i>Blood</i> , 2016, 128, 1821-1828.	1.4	98
59	A randomized phase III study of carfilzomib vs low-dose corticosteroids with optional cyclophosphamide in relapsed and refractory multiple myeloma (FOCUS). <i>Leukemia</i> , 2017, 31, 107-114.	7.2	98
60	European Perspective on Multiple Myeloma Treatment Strategies in 2014. <i>Oncologist</i> , 2014, 19, 829-844.	3.7	90
61	Ixazomib significantly prolongs progression-free survival in high-risk relapsed/refractory myeloma patients. <i>Blood</i> , 2017, 130, 2610-2618.	1.4	90
62	Triplet vs doublet lenalidomide-containing regimens for the treatment of elderly patients with newly diagnosed multiple myeloma. <i>Blood</i> , 2016, 127, 1102-1108.	1.4	78
63	Lenalidomide and low-dose dexamethasone for newly diagnosed primary plasma cell leukemia. <i>Leukemia</i> , 2014, 28, 222-225.	7.2	77
64	Monoclonal antibodies in the treatment of multiple myeloma: current status and future perspectives. <i>Leukemia</i> , 2016, 30, 526-535.	7.2	76
65	Long-term results of the GIMEMA VEL-03-096 trial in MM patients receiving VTD consolidation after ASCT: MRD kinetics' impact on survival. <i>Leukemia</i> , 2015, 29, 689-695.	7.2	75
66	Developments in continuous therapy and maintenance treatment approaches for patients with newly diagnosed multiple myeloma. <i>Blood Cancer Journal</i> , 2020, 10, 17.	6.2	75
67	Randomized Clinical Trial Representativeness and Outcomes in Real-World Patients: Comparison of 6 Hallmark Randomized Clinical Trials of Relapsed/Refractory Multiple Myeloma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2020, 20, 8-17.e16.	0.4	74
68	Safety of thalidomide in newly diagnosed elderly myeloma patients: a meta-analysis of data from individual patients in six randomized trials. <i>Haematologica</i> , 2013, 98, 87-94.	3.5	73
69	Shifts in the Therapeutic Paradigm for Patients Newly Diagnosed with Multiple Myeloma: Maintenance Therapy and Overall Survival. <i>Clinical Cancer Research</i> , 2011, 17, 1253-1263.	7.0	72
70	Proteomic characterization of human multiple myeloma bone marrow extracellular matrix. <i>Leukemia</i> , 2017, 31, 2426-2434.	7.2	72
71	Health-Related Quality-of-Life Results From the Open-Label, Randomized, Phase III ASPIRE Trial Evaluating Carfilzomib, Lenalidomide, and Dexamethasone Versus Lenalidomide and Dexamethasone in Patients With Relapsed Multiple Myeloma. <i>Journal of Clinical Oncology</i> , 2016, 34, 3921-3930.	1.6	70
72	Proteomic characterization of circulating extracellular vesicles identifies novel serum myeloma associated markers. <i>Journal of Proteomics</i> , 2016, 136, 89-98.	2.4	68

#	ARTICLE	IF	CITATIONS
73	Management of older adults with multiple myeloma. <i>Blood Reviews</i> , 2013, 27, 133-142.	5.7	67
74	Efficacy of carfilzomib lenalidomide dexamethasone (KRd) with or without transplantation in newly diagnosed myeloma according to risk status: Results from the FORTE trial.. <i>Journal of Clinical Oncology</i> , 2019, 37, 8002-8002.	1.6	67
75	Phase 2 study of carfilzomib, thalidomide, and dexamethasone as induction/consolidation therapy for newly diagnosed multiple myeloma. <i>Blood</i> , 2015, 125, 449-456.	1.4	60
76	Ixazomib as Postinduction Maintenance for Patients With Newly Diagnosed Multiple Myeloma Not Undergoing Autologous Stem Cell Transplantation: The Phase III TOURMALINE-MM4 Trial. <i>Journal of Clinical Oncology</i> , 2020, 38, 4030-4041.	1.6	56
77	Double Vs Single Autologous Stem Cell Transplantation After Bortezomib-Based Induction Regimens For Multiple Myeloma: An Integrated Analysis Of Patient-Level Data From Phase European III Studies. <i>Blood</i> , 2013, 122, 767-767.	1.4	56
78	Circulating miRNA markers show promise as new prognosticators for multiple myeloma. <i>Leukemia</i> , 2014, 28, 1922-1926.	7.2	55
79	Whole-exome sequencing of primary plasma cell leukemia discloses heterogeneous mutational patterns. <i>Oncotarget</i> , 2015, 6, 17543-17558.	1.8	55
80	Carfilzomib+“lenalidomide+“dexamethasone vs lenalidomide+“dexamethasone in relapsed multiple myeloma by previous treatment. <i>Blood Cancer Journal</i> , 2017, 7, e554-e554.	6.2	54
81	Venous and arterial thrombotic risks with thalidomide: evidence and practical guidance. <i>Therapeutic Advances in Drug Safety</i> , 2012, 3, 255-266.	2.4	51
82	Age and aging in blood disorders: multiple myeloma. <i>Haematologica</i> , 2014, 99, 1133-1137.	3.5	50
83	Carfilzomib+“dexamethasone vs bortezomib+“dexamethasone in relapsed or refractory multiple myeloma by cytogenetic risk in the phase 3 study ENDEAVOR. <i>Leukemia</i> , 2017, 31, 1368-1374.	7.2	50
84	Activated idiotype-reactive cells in suppressor/cytotoxic subpopulations of monoclonal gammopathies: correlation with diagnosis and disease status. <i>Blood</i> , 1988, 72, 1064-1068.	1.4	48
85	Management of patients with multiple myeloma beyond the clinical-trial setting: understanding the balance between efficacy, safety and tolerability, and quality of life. <i>Blood Cancer Journal</i> , 2021, 11, 40.	6.2	46
86	Activated idiotype-reactive cells in suppressor/cytotoxic subpopulations of monoclonal gammopathies: correlation with diagnosis and disease status. <i>Blood</i> , 1988, 72, 1064-1068.	1.4	44
87	Bortezomib cumulative dose, efficacy, and tolerability with three different bortezomib-melphalan-prednisone regimens in previously untreated myeloma patients ineligible for high-dose therapy. <i>Haematologica</i> , 2014, 99, 1114-1122.	3.5	42
88	How to Manage Neutropenia in Multiple Myeloma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2012, 12, 5-11.	0.4	40
89	Pomalidomide and Low-Dose Dexamethasone Improves Health-Related Quality of Life and Prolongs Time to Worsening in Relapsed/Refractory Patients With Multiple Myeloma Enrolled in the MM-003 Randomized Phase III Trial. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2015, 15, 519-530.	0.4	40
90	Lenalidomide (LEN) maintenance (MNTC) after high-dose melphalan and autologous stem cell transplant (ASCT) in multiple myeloma (MM): A meta-analysis (MA) of overall survival (OS).. <i>Journal of Clinical Oncology</i> , 2016, 34, 8001-8001.	1.6	40

#	ARTICLE	IF	CITATIONS
91	Lenalidomide: A new therapy for multiple myeloma. <i>Cancer Treatment Reviews</i> , 2008, 34, 283-291.	7.7	39
92	Once-weekly carfilzomib, pomalidomide, and low-dose dexamethasone for relapsed/refractory myeloma: a phase I/II study. <i>Leukemia</i> , 2018, 32, 1803-1807.	7.2	39
93	A phase 2 study of three low-dose intensity subcutaneous bortezomib regimens in elderly frail patients with untreated multiple myeloma. <i>Leukemia</i> , 2016, 30, 1320-1326.	7.2	38
94	Prolonged Duration of Therapy Is Associated With Improved Survival in Patients Treated for Relapsed/Refractory Multiple Myeloma in Routine Clinical Care in the United States. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2018, 18, 152-160.	0.4	34
95	Real-world outcomes and factors impacting treatment choice in relapsed and/or refractory multiple myeloma (RRMM): a comparison of VRd, KRd, and IRd. <i>Expert Review of Hematology</i> , 2020, 13, 421-433.	2.2	34
96	Have drug combinations supplanted stem cell transplantation in myeloma?. <i>Blood</i> , 2012, 120, 4692-4698.	1.4	33
97	The genetic and genomic background of multiple myeloma patients achieving complete response after induction therapy with bortezomib, thalidomide and dexamethasone (VTD). <i>Oncotarget</i> , 2016, 7, 9666-9679.	1.8	33
98	Prospective molecular monitoring of minimal residual disease after non-myeloablative allografting in newly diagnosed multiple myeloma. <i>Leukemia</i> , 2016, 30, 1211-1214.	7.2	33
99	Tumor-Stroma Ratio is an independent predictor for overall survival and disease free survival in gastric cancer patients. <i>Journal of the Royal College of Surgeons of Edinburgh</i> , 2017, 15, 329-335.	1.8	33
100	Minimal residual disease after transplantation or lenalidomide-based consolidation in myeloma patients: a prospective analysis. <i>Oncotarget</i> , 2017, 8, 5924-5935.	1.8	33
101	Minimal residual disease by flow cytometry and allelic-specific oligonucleotide real-time quantitative polymerase chain reaction in patients with myeloma receiving lenalidomide maintenance: A pooled analysis. <i>Cancer</i> , 2019, 125, 750-760.	4.1	31
102	Clinical characteristics of patients with relapsed multiple myeloma. <i>Cancer Treatment Reviews</i> , 2015, 41, 827-835.	7.7	30
103	Safety and Efficacy of Daratumumab with Lenalidomide and Dexamethasone in Relapsed or Relapsed, Refractory Multiple Myeloma. <i>Blood</i> , 2014, 124, 84-84.	1.4	30
104	Lenalidomide-based induction and maintenance in elderly newly diagnosed multiple myeloma patients: updated results of the EMN01 randomized trial. <i>Haematologica</i> , 2020, 105, 1937-1947.	3.5	29
105	Pomalidomide plus low-dose dexamethasone in patients with relapsed/refractory multiple myeloma and moderate renal impairment: a pooled analysis of three clinical trials. <i>Leukemia and Lymphoma</i> , 2016, 57, 2833-2838.	1.3	27
106	Prognostic or predictive value of circulating cytokines and angiogenic factors for initial treatment of multiple myeloma in the GIMEMA MM0305 randomized controlled trial. <i>Journal of Hematology and Oncology</i> , 2019, 12, 4.	17.0	27
107	Serial Echocardiographic Assessment of Patients (Pts) with Relapsed Multiple Myeloma (RMM) Receiving Carfilzomib and Dexamethasone (Kd) Vs Bortezomib and Dexamethasone (Vd): A Substudy of the Phase 3 Endeavor Trial (NCT01568866). <i>Blood</i> , 2015, 126, 4250-4250.	1.4	27
108	Phase 1/2 study of weekly carfilzomib, cyclophosphamide, dexamethasone in newly diagnosed transplant-ineligible myeloma. <i>Leukemia</i> , 2018, 32, 979-985.	7.2	25

#	ARTICLE	IF	CITATIONS
109	Early mortality in myeloma patients treated with first-generation novel agents thalidomide, lenalidomide, bortezomib at diagnosis: A pooled analysis. <i>Critical Reviews in Oncology/Hematology</i> , 2018, 130, 27-35.	4.4	25
110	Phase II study of carfilzomib, thalidomide, and low-dose dexamethasone as induction and consolidation in newly diagnosed, transplant eligible patients with multiple myeloma; the Carthadex trial. <i>Haematologica</i> , 2019, 104, 2265-2273.	3.5	23
111	A Phase III Study to Determine the Efficacy and Safety of Lenalidomide in Combination with Melphalan and Prednisone (MPR) in Elderly Patients with Newly Diagnosed Multiple Myeloma.. <i>Blood</i> , 2009, 114, 613-613.	1.4	23
112	Once-weekly versus twice-weekly carfilzomib in patients with newly diagnosed multiple myeloma: a pooled analysis of two phase I/II studies. <i>Haematologica</i> , 2019, 104, 1640-1647.	3.5	22
113	Preliminary Results from a Phase 1b Study of TAK-079, an Investigational Anti-CD38 Monoclonal Antibody (mAb) in Patients with Relapsed/ Refractory Multiple Myeloma (RRMM). <i>Blood</i> , 2019, 134, 140-140.	1.4	22
114	Successful mobilization of PBSCs predicts favorable outcomes in multiple myeloma patients treated with novel agents and autologous transplantation. <i>Bone Marrow Transplantation</i> , 2015, 50, 673-678.	2.4	21
115	Real-world comparative effectiveness of triplets containing bortezomib (B), carfilzomib (C), daratumumab (D), or ixazomib (I) in relapsed/refractory multiple myeloma (RRMM) in the US. <i>Annals of Hematology</i> , 2021, 100, 2325-2337.	1.8	21
116	A Phase III Study Of ASCT Vs Cyclophosphamide-Lenalidomide-Dexamethasone and Lenalidomide-Prednisone Maintenance Vs Lenalidomide Alone In Newly Diagnosed Myeloma Patients. <i>Blood</i> , 2013, 122, 763-763.	1.4	20
117	Time to first disease progression, but not β_2 -microglobulin, predicts outcome in myeloma patients who receive thalidomide as salvage therapy. <i>Cancer</i> , 2007, 110, 824-829.	4.1	19
118	Lenalidomide and low-dose dexamethasone (Rd) versus bortezomib, melphalan, prednisone (VMP) in elderly newly diagnosed multiple myeloma patients: A comparison of two prospective trials. <i>American Journal of Hematology</i> , 2017, 92, 244-250.	4.1	19
119	Optimizing Treatment for Elderly Patients With Newly Diagnosed Multiple Myeloma: A Personalized Approach. <i>Journal of Clinical Oncology</i> , 2016, 34, 3600-3604.	1.6	18
120	Natural History of Multiple Myeloma Relapsing After Therapy with IMiDs and Bortezomib: A Multicenter International Myeloma Working Group Study.. <i>Blood</i> , 2009, 114, 2878-2878.	1.4	18
121	Diagnosis and therapy of multiple myeloma. <i>Korean Journal of Internal Medicine</i> , 2013, 28, 263.	1.7	17
122	Strategy for the treatment of multiple myeloma utilizing monoclonal antibodies: A new era begins. <i>Leukemia and Lymphoma</i> , 2016, 57, 537-556.	1.3	17
123	A Phase III Study of Enoxaparin Versus Low-Dose Warfarin Versus Aspirin as Thromboprophylaxis for Patients with Newly Diagnosed Multiple Myeloma Treated up-Front with Thalidomide-Containing Regimens. <i>Blood</i> , 2008, 112, 3017-3017.	1.4	17
124	A Phase III Study of Enoxaparin Vs Aspirin as Thromboprophylaxis for Newly Diagnosed Myeloma Patients Treated with Lenalidomide-Based Regimen.. <i>Blood</i> , 2010, 116, 1092-1092.	1.4	17
125	Reduced Dose-Intensity Subcutaneous Bortezomib Plus Prednisone (VP) Or Plus Cyclophosphamide (VCP) Or Plus Melphalan (VMP) For Newly Diagnosed Multiple Myeloma Patients Older Than 75 Years Of Age. <i>Blood</i> , 2013, 122, 539-539.	1.4	17
126	First-line therapy with either bortezomib-melphalan-prednisone or lenalidomide-dexamethasone followed by lenalidomide for transplant-ineligible multiple myeloma patients: a pooled analysis of two randomized trials. <i>Haematologica</i> , 2020, 105, 1074-1080.	3.5	16

#	ARTICLE	IF	CITATIONS
127	Bortezomib, Melphalan, Prednisone and Thalidomide (VMPT) Followed by Maintenance with Bortezomib and Thalidomide for Initial Treatment of Elderly Multiple Myeloma Patients.. Blood, 2009, 114, 128-128.	1.4	16
128	Continued Overall Survival Benefit After 5 Years' Follow-up with Bortezomib-Melphalan-Prednisone (VMP) Versus Melphalan-Prednisone (MP) in Patients with Previously Untreated Multiple Myeloma, and No Increased Risk of Second Primary Malignancies: Final Results of the Phase 3 VISTA Trial. Blood, 2011, 118, 476-476.	1.4	16
129	Vantage 088: Vorinostat in Combination with Bortezomib in Patients with Relapsed/Refractory Multiple Myeloma: Results of a Global, Randomized Phase 3 Trial. Blood, 2011, 118, 811-811.	1.4	16
130	Carfilzomib and pomalidomide in patients with relapsed and/or refractory multiple myeloma with baseline risk factors. Annals of Oncology, 2015, 26, 2247-2256.	1.2	15
131	A Simple Score, Based On Geriatric Assessment, Improves Prediction of Survival, and Risk Of Serious Adverse Events In Elderly Newly Diagnosed Multiple Myeloma Patients. Blood, 2013, 122, 687-687.	1.4	15
132	Melphalan/prednisone/lenalidomide (MPR) versus high-dose melphalan and autologous transplantation (MEL200) plus lenalidomide maintenance or no maintenance in newly diagnosed multiple myeloma (MM) patients.. Journal of Clinical Oncology, 2013, 31, 8509-8509.	1.6	15
133	Minimal residual disease (MRD) monitoring by multiparameter flow cytometry (MFC) in newly diagnosed transplant eligible multiple myeloma (MM) patients: Results from the EMN02/HO95 phase 3 trial.. Journal of Clinical Oncology, 2017, 35, 8011-8011.	1.6	15
134	Maintenance Therapy for Multiple Myeloma. Hematology/Oncology Clinics of North America, 2014, 28, 839-859.	2.2	14
135	A Phase III Study of Enoxaparin vs Aspirin vs Low-Dose Warfarin as Thromboprophylaxis for Newly Diagnosed Myeloma Patients Treated with Thalidomide Based-Regimens.. Blood, 2009, 114, 492-492.	1.4	14
136	Novel investigational drugs active as single agents in multiple myeloma. Expert Opinion on Investigational Drugs, 2017, 26, 699-711.	4.1	13
137	Continuous therapy in standard- and high-risk newly-diagnosed multiple myeloma: A pooled analysis of 2 phase III trials. Critical Reviews in Oncology/Hematology, 2018, 132, 9-16.	4.4	13
138	Overall Survival Benefit for Bortezomib-Melphalan-Prednisone-Thalidomide Followed by Maintenance with Bortezomib-Thalidomide (VMPT-VT) Versus Bortezomib-Melphalan-Prednisone (VMP) in Newly Diagnosed Multiple Myeloma Patients. Blood, 2012, 120, 200-200.	1.4	13
139	A Randomized Phase 3 Trial Of Melphalan-Lenalidomide-Prednisone (MPR) Or Cyclophosphamide-Prednisone-Lenalidomide (CPR) Vs Lenalidomide Plus Dexamethasone (Rd) In Elderly Newly Diagnosed Multiple Myeloma Patients. Blood, 2013, 122, 536-536.	1.4	13
140	Carfilzomib-lenalidomide-dexamethasone (KRd) vs carfilzomib-cyclophosphamide-dexamethasone (KCd) induction: Planned interim analysis of the randomized FORTE trial in newly diagnosed multiple myeloma (NDMM).. Journal of Clinical Oncology, 2017, 35, 8003-8003.	1.6	13
141	Bendamustine for the treatment of multiple myeloma in first-line and relapsed/refractory settings: a review of clinical trial data. Leukemia and Lymphoma, 2015, 56, 559-567.	1.3	12
142	Carfilzomib, cyclophosphamide and dexamethasone for newly diagnosed, high-risk myeloma patients not eligible for transplant: a pooled analysis of two studies. Haematologica, 2021, 106, 1079-1085.	3.5	12
143	A Phase 3 Study Evaluating the Efficacy and Safety of Lenalidomide (Len) Combined with Melphalan and Prednisone Followed by Continuous Lenalidomide Maintenance (MPR-R) in Patients (Pts) ≥ 65 Years (Yrs) with Newly Diagnosed Multiple Myeloma (NDMM): Updated Results for Pts Aged 65-75 Yrs Enrolled in MM-015. Blood, 2011, 118, 475-475.	1.4	12
144	A Prospective, Randomized Study of Melphalan, Prednisone, Lenalidomide (MPR) versus Melphalan (200) Tj ETQqO O O rgBT /Overlock 10 Analysis.. Blood, 2009, 114, 350-350.	1.4	11

#	ARTICLE	IF	CITATIONS
145	Melphalan/Prednisone/Lenalidomide (MPR) Versus High-Dose Melphalan and Autologous Transplantation (MEL200) in Newly Diagnosed Multiple Myeloma (MM) Patients <65 Years: Results of a Randomized Phase III Study. <i>Blood</i> , 2011, 118, 3069-3069.	1.4	11
146	Maintenance Therapy With Lenalidomide Significantly Improved Survival Of Yong Newly Diagnosed Multiple Myeloma Patients. <i>Blood</i> , 2013, 122, 2089-2089.	1.4	11
147	PFS2 In Elderly Patients With Newly Diagnosed Multiple Myeloma (NDMM): Results From The MM-015 Study. <i>Blood</i> , 2013, 122, 405-405.	1.4	11
148	A Randomized Phase III Trial of Melphalan and Dexamethasone (MDex) Versus Bortezomib, Melphalan and Dexamethasone (BMDex) for Untreated Patients with AL Amyloidosis. <i>Blood</i> , 2014, 124, 35-35.	1.4	11
149	Pseudopyloric Metaplasia Is Not Associated With the Development of Gastric Cancer. <i>American Journal of Gastroenterology</i> , 2021, 116, 1859-1867.	0.4	10
150	Pomalidomide + Low-Dose Dexamethasone in Patients with Refractory or Relapsed and Refractory Multiple Myeloma and Renal Impairment: Analysis of Patients from the Phase 3b Stratus Trial (MM-010). <i>Blood</i> , 2014, 124, 4755-4755.	1.4	10
151	Global Myeloma Research Clusters, Output, and Citations: A Bibliometric Mapping and Clustering Analysis. <i>PLoS ONE</i> , 2015, 10, e0116966.	2.5	10
152	Multiple myeloma: is a shift toward continuous therapy needed to move forward?. <i>Expert Review of Hematology</i> , 2015, 8, 253-256.	2.2	9
153	Treatment of Newly Diagnosed Elderly Multiple Myeloma. <i>Cancer Treatment and Research</i> , 2016, 169, 123-143.	0.5	9
154	Bendamustine, Low-dose dexamethasone, and lenalidomide (BdL) for the treatment of patients with relapsed/refractory multiple myeloma confirms very promising results in a phase I/II study. <i>Leukemia and Lymphoma</i> , 2017, 58, 552-559.	1.3	9
155	Treatment Intensification With Autologous Stem Cell Transplantation and Lenalidomide Maintenance Improves Survival Outcomes of Patients With Newly Diagnosed Multiple Myeloma in Complete Response. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2018, 18, 533-540.	0.4	9
156	Maintenance in myeloma patients achieving complete response after upfront therapy: a pooled analysis. <i>Journal of Cancer Research and Clinical Oncology</i> , 2018, 144, 1357-1366.	2.5	8
157	Impact of Bortezomib Incorporated Into Autotransplantation On Outcomes of Myeloma Patients with High-Risk Cytogenetics: An Integrated Analysis of 1894 Patients Enrolled in Four European Phase 3 Studies. <i>Blood</i> , 2012, 120, 749-749.	1.4	8
158	Circulating Mir-16 and Mir-25 As New Prognosticators For Multiple Myeloma. <i>Blood</i> , 2013, 122, 1853-1853.	1.4	8
159	A Phase II Study With Carfilzomib, Cyclophosphamide and Dexamethasone (CCd) For Newly Diagnosed Multiple Myeloma. <i>Blood</i> , 2013, 122, 685-685.	1.4	8
160	Efficacy and safety of ixazomib plus lenalidomide-dexamethasone (IRd) vs placebo-rd in patients (pts) with relapsed/refractory multiple myeloma (RRMM) by cytogenetic risk status in the global phase III Tourmaline-MM1 study.. <i>Journal of Clinical Oncology</i> , 2016, 34, 8018-8018.	1.6	8
161	Novel treatment paradigm for elderly patients with multiple myeloma. <i>American Journal of Blood Research</i> , 2011, 1, 190-204.	0.6	8
162	Role of Consolidation/Maintenance Therapy in Multiple Myeloma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2013, 13, S349-S354.	0.4	7

#	ARTICLE	IF	CITATIONS
163	Stem cell transplantation in multiple myeloma and other plasma cell disorders (report from an EBMT) Tj ETQq1 1 0.784314 rgBT /Ove	1.3	7
164	Lenalidomide Maintenance with or without Prednisone in Newly Diagnosed Myeloma Patients: A Pooled Analysis. <i>Cancers</i> , 2019, 11, 1735.	3.7	7
165	Carfilzomib Combined with Thalidomide and Dexamethasone (CARTHADEX) As Induction Treatment Prior to High-Dose Melphalan (HDM) in Newly Diagnosed Patients with Multiple Myeloma (MM). A Trial of the European Myeloma Network EMN. <i>Blood</i> , 2011, 118, 633-633.	1.4	7
166	Phase 2 Study of Carfilzomib, Thalidomide, and Low-Dose Dexamethasone As Induction/Consolidation in Newly Diagnosed, Transplant Eligible Patients with Multiple Myeloma, the Carthadex Trial. <i>Blood</i> , 2016, 128, 1141-1141.	1.4	7
167	Part II: Role of Maintenance Therapy in Transplant-Ineligible Patients. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2013, 11, 43-49.	4.9	6
168	A prospective observational study to assess clinical decision-making, prognosis, quality of life and satisfaction with care in patients with relapsed/refractory multiple myeloma: the CLARITY study protocol. <i>Health and Quality of Life Outcomes</i> , 2018, 16, 127.	2.4	6
169	Impact of FISH and Cytogenetics On Overall and Event Free Survival in Myeloma: An IMWG Analysis of 9,897 Patients.. <i>Blood</i> , 2009, 114, 743-743.	1.4	6
170	Bortezomib-Based Induction Treatments Improve Outcomes of Newly Diagnosed Multiple Myeloma Patients with High-Risk Cytogenetic Abnormalities. <i>Blood</i> , 2010, 116, 781-781.	1.4	6
171	Pomalidomide Cyclophosphamide and Prednisone (PCP) Treatment for Relapsed/Refractory Multiple Myeloma. <i>Blood</i> , 2012, 120, 446-446.	1.4	6
172	A Multicenter, Open Label Phase I/II Study of Carfilzomib, Pomalidomide and Dexamethasone in Relapsed and/or Refractory Multiple Myeloma (MM) Patients. <i>Blood</i> , 2016, 128, 1145-1145.	1.4	6
173	Second primary malignancies (SPM) in newly diagnosed myeloma (MM) patients treated with lenalidomide (Len): Meta-analysis of 6,383 individual patient data (IPD).. <i>Journal of Clinical Oncology</i> , 2013, 31, 8517-8517.	1.6	6
174	Continuous treatment (CT) versus fixed duration of therapy (FDT) in newly diagnosed myeloma patients: PFS1, PFS2, OS endpoints.. <i>Journal of Clinical Oncology</i> , 2014, 32, 8515-8515.	1.6	6
175	Histological growth patterns and molecular analysis of resected colorectal lung metastases. <i>Pathology Research and Practice</i> , 2021, 222, 153414.	2.3	5
176	Have drug combinations supplanted stem cell transplantation in myeloma?. <i>Hematology American Society of Hematology Education Program</i> , 2012, 2012, 335-341.	2.5	5
177	Defibrotide (DF), an Orally Bioavailable Modulator of Myeloma Tumor-Microenvironment Interactions: Molecular Sequelae and Clinical Implications.. <i>Blood</i> , 2006, 108, 3523-3523.	1.4	5
178	The Weekly Infusion of Bortezomib Reduces Peripheral Neuropathy.. <i>Blood</i> , 2009, 114, 3887-3887.	1.4	5
179	A Multicenter, Open Label Study of Oral Lenalidomide and Prednisone (RP) Followed by Oral Lenalidomide Melphalan and Prednisone (MPR) and Oral Lenalidomide Maintenance In Newly Diagnosed Elderly Multiple Myeloma Patients. <i>Blood</i> , 2010, 116, 1940-1940.	1.4	5
180	Analysis of Second-Line Lenalidomide Following Initial Relapse in the MM-015 Trial. <i>Blood</i> , 2012, 120, 944-944.	1.4	5

#	ARTICLE	IF	CITATIONS
181	Doublet Vs Triplet Lenalidomide-Containing Regimens in Newly Diagnosed Myeloma Patients, Younger or Older Than 75 Years: Subgroup Analysis of a Phase III Study. <i>Blood</i> , 2014, 124, 2110-2110.	1.4	5
182	Cell-Free DNA for Minimal Residual Disease Monitoring in Multiple Myeloma Patients. <i>Blood</i> , 2014, 124, 3423-3423.	1.4	5
183	Carfilzomib in Combination with Bendamustine and Dexamethasone (CBd) in Relapsed and/or Refractory Patients with Multiple Myeloma: The Phase I/II EMN09 Study. <i>Blood</i> , 2016, 128, 3334-3334.	1.4	5
184	Prognostic Impact of Minimal Residual Disease By ASO-RQ-PCR in Multiple Myeloma: A Pooled Analysis of 2 Phase III Studies in Patients Treated with Lenalidomide after Front-Line Therapy. <i>Blood</i> , 2016, 128, 4409-4409.	1.4	5
185	Twin randomized studies of daratumumab (DARA; D) plus standard of care (lenalidomide/dexamethasone or bortezomib/dexamethasone [DRd or DVd]) versus Rd or Vd alone in relapsed or refractory multiple myeloma (MM): 54767414MMY3003 (Pollux) and 54767414MMY3004 (Castor).. <i>Journal of Clinical Oncology</i> , 2015, 33, TPS8609-TPS8609.	1.6	5
186	Carfilzomib, bendamustine, and dexamethasone in patients with advanced multiple myeloma: The EMN09 phase 1/2 study of the European Myeloma Network. <i>Cancer</i> , 2021, 127, 3413-3421.	4.1	4
187	Optimal Treatment Sequencing In Multiple Myeloma: An Exploratory Modeling Approach. <i>Blood</i> , 2010, 116, 3046-3046.	1.4	4
188	A Phase I/II Study of Pomalidomide-Cyclophosphamide-Prednisone (PCP) in Patients with Multiple Myeloma Relapsed/Refractory to Lenalidomide. <i>Blood</i> , 2011, 118, 632-632.	1.4	4
189	Carfilzomib, Cyclophosphamide and Dexamethasone (CCd) for Newly Diagnosed Multiple Myeloma (MM) Patients. <i>Blood</i> , 2012, 120, 730-730.	1.4	4
190	Weekly Carfilzomib, Cyclophosphamide and Dexamethasone (wCCd) in Newly Diagnosed Multiple Myeloma Patients: A Phase I- II Study. <i>Blood</i> , 2014, 124, 175-175.	1.4	4
191	Weekly Carfilzomib, Cyclophosphamide and Dexamethasone (wCCyd) in Elderly Newly Diagnosed Multiple Myeloma Patients: Results of a Phase 2 Study. <i>Blood</i> , 2015, 126, 1828-1828.	1.4	4
192	Autologous Transplantation Versus Cyclophosphamide-Lenalidomide-Prednisone Followed By Lenalidomide-Prednisone Versus Lenalidomide Maintenance in Multiple Myeloma: Long-Term Results of a Phase III Trial. <i>Blood</i> , 2015, 126, 392-392.	1.4	4
193	Two phase 3 studies of the oral proteasome inhibitor (PI) ixazomib for multiple myeloma (MM) in the maintenance setting: TOURMALINE-MM3, and -MM4.. <i>Journal of Clinical Oncology</i> , 2016, 34, TPS8068-TPS8068.	1.6	4
194	Curative and Prophylactic Surgery of Young-onset Colorectal Cancer in Inherited Syndromes: A 15-Year Monocentric Retrospective Experience. <i>Anticancer Research</i> , 2019, 39, 3131-3136.	1.1	3
195	Monoclonal antibodies for treating multiple myeloma - a new era, new safety considerations?. <i>Expert Opinion on Drug Safety</i> , 2016, 15, 1295-1300.	2.4	3
196	Bortezomib Plus Melphalanâ€“Prednisone Continues to Demonstrate a Survival Benefit Vs Melphalanâ€“Prednisone in the Phase III VISTA Trial in Previously Untreated Multiple Myeloma After 3 Years' Follow-up and Extensive Subsequent Therapy Use.. <i>Blood</i> , 2009, 114, 3859-3859.	1.4	3
197	Correlation Between Clinical Outcome and Disease Kinetics by Quantitative PCR in Myeloma Patients Following Post-Transplant Consolidation with Bortezomib, Thalidomide and Dexamethasone.. <i>Blood</i> , 2009, 114, 960-960.	1.4	3
198	A Phase III Study to Compare Melphalan, Prednisone, Lenalidomide (MPR) Versus Melphalan 200 Mg/m2 and Autologous Transplantation (MEL200) In Newly Diagnosed Multiple Myeloma Patients. <i>Blood</i> , 2010, 116, 3573-3573.	1.4	3

#	ARTICLE	IF	CITATIONS
199	Melphalan, Prednisone and Lenalidomide Followed by Lenalidomide Maintenance Improves Health-Related Quality of Life (HRQoL), with Newly Diagnosed Multiple Myeloma (NDMM) Patients ≥ 65 Years Benefiting From Delays in Disease Progression. <i>Blood</i> , 2011, 118, 3157-3157.	1.4	3
200	Second Primary Malignancies in Newly Diagnosed Multiple Myeloma Patients Treated with Lenalidomide: Analysis of Pooled Data in 2459 Patients. <i>Blood</i> , 2011, 118, 996-996.	1.4	3
201	Circulating Mir-130a in Multiple Myeloma and Extramedullary Myeloma Patients. <i>Blood</i> , 2014, 124, 2043-2043.	1.4	3
202	The Presence of FDG PET/CT Focal, Not Osteolytic, Lesion(s) Identifies a Sub-Group of Patients with Smoldering Multiple Myeloma with High-Risk of Progression into Symptomatic Disease. <i>Blood</i> , 2014, 124, 3371-3371.	1.4	3
203	Sustained disease control in transplant-ineligible patients: the role of continuous therapy. <i>Leukemia Research</i> , 2012, 36, S19-S26.	0.8	2
204	Immunotherapy: the next step in the treatment of myeloma. <i>Lancet Haematology</i> , 2015, 2, e504-e505.	4.6	2
205	Case report: skin injury after contact with a red spine starfish, <i>Protoreaster lincki</i> . <i>Contact Dermatitis</i> , 2018, 78, 95-96.	1.4	2
206	Carfilzomib Combined With Thalidomide and Low-Dose Dexamethasone for Remission Induction and Consolidation in Newly Diagnosed Transplant Eligible Patients With Multiple Myeloma: 8 vs 4 Induction Cycles; the Carthadex Trial. <i>HemaSphere</i> , 2020, 4, e370.	2.7	2
207	Have drug combinations supplanted stem cell transplantation in myeloma?. <i>Hematology American Society of Hematology Education Program</i> , 2012, 2012, 335-41.	2.5	2
208	Neuropathy in Multiple Myeloma Patients Treated with Bortezomib: A Multicenter Experience.. <i>Blood</i> , 2007, 110, 4823-4823.	1.4	2
209	Clinical Outcomes According to Genomic Abnormalities in 566 Newly Diagnosed Multiple Myeloma Patients Treated with Bortezomib-Based Regimens.. <i>Blood</i> , 2009, 114, 1868-1868.	1.4	2
210	Long-Term Follow up of a Comparison of Non-Myeloablative Allografting with Autografting for Newly Diagnosed Myeloma. <i>Blood</i> , 2010, 116, 525-525.	1.4	2
211	Melphalan, Prednisone and Lenalidomide Followed by Lenalidomide Maintenance Displays Treatment Characteristics Favourable to Global Quality of Life in Newly Diagnosed Multiple Myeloma (NDMM) Patients ≥ 65 Years,. <i>Blood</i> , 2011, 118, 3988-3988.	1.4	2
212	Improved Igh-Based MRD Detection By Using Droplet Digital PCR: a Comparison With Real Time Quantitative PCR In MCL and MM. <i>Blood</i> , 2013, 122, 4290-4290.	1.4	2
213	In Multiple Myeloma, Minimal Residual Disease (MRD) Is an Early Predictor of Progression and Is Modulated By Maintenance Therapy with Lenalidomide. <i>Blood</i> , 2014, 124, 3394-3394.	1.4	2
214	Safety and Efficacy in the Stratus (MM-010) Trial, a Single-Arm Phase 3b Study Evaluating Pomalidomide + Low-Dose Dexamethasone in Patients with Refractory or Relapsed and Refractory Multiple Myeloma. <i>Blood</i> , 2014, 124, 80-80.	1.4	2
215	Updated efficacy data and MRD analysis according to risk status in newly diagnosed myeloma patients treated with carfilzomib + lenalidomide or cyclophosphamide (FORTE trial).. <i>Journal of Clinical Oncology</i> , 2018, 36, 8009-8009.	1.6	2
216	Minimal Residual Disease Monitoring During Maintenance In Multiple Myeloma Patients. <i>Blood</i> , 2013, 122, 3126-3126.	1.4	2

#	ARTICLE	IF	CITATIONS
217	Mutational activation of N- and K-ras oncogenes in plasma cell dyscrasias. <i>Blood</i> , 1993, 81, 2708-2713.	1.4	2
218	Impact of Complete Response on Survival with Either Autologous Stem Cell Transplantation or Conventional Chemotherapy: Results of a Pooled Analysis of 5 Phase III Trials in Newly Diagnosed Multiple Myeloma Patients. <i>Blood</i> , 2015, 126, 927-927.	1.4	2
219	The Binding of CD38 Therapeutics to Red Blood Cells and Platelets Subverts Depletion of Target Cells. <i>Blood</i> , 2019, 134, 3136-3136.	1.4	2
220	Stem Cell Transplantation in Multiple Myeloma. <i>Current Cancer Drug Targets</i> , 2017, 17, 769-781.	1.6	2
221	Optimizing multiple myeloma treatment: conclusions. <i>Leukemia Research</i> , 2012, 36, S44-S45.	0.8	1
222	Autologous Transplantation in Elderly Multiple Myeloma Patients: Is the Procedure Cost Effective?. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 1705-1706.	2.0	1
223	Frail Patients with Newly Diagnosed Multiple Myeloma. , 2018, , 539-549.		1
224	Sequential Approach with Bortezomib as Induction Before Autologous Transplantation, Followed by Lenalidomide as Consolidation-Maintenance in Untreated Multiple Myeloma Patients.. <i>Blood</i> , 2009, 114, 3419-3419.	1.4	1
225	Analysis of Transcriptome, Mirnome and Genomic Profiles in Association with Clinical Outcome in a Prospective Series of Primary Plasma Cell Leukemia. <i>Blood</i> , 2012, 120, 3938-3938.	1.4	1
226	Lenalidomide and Low Dose Dexamethasone As First Line Therapy for Newly Diagnosed Patients with Primary Plasma Cell Leukemia. <i>Blood</i> , 2012, 120, 729-729.	1.4	1
227	Next-Generation Sequencing and Real-Time Quantitative PCR for Minimal Residual Disease (MRD) Detection Using the Immunoglobulin Heavy Chain Variable Region: A Methodical Comparison in Acute Lymphoblastic Leukemia (ALL), Mantle Cell Lymphoma (MCL) and Multiple Myeloma (MM). <i>Blood</i> , 2012, 120, 788-788.	1.4	1
228	Bendamustine, Low-Dose Dexamethasone, and Lenalidomide (BdL) For The Treatment Of Patients With Relapsed Multiple Myeloma Confirms Very Promising Results In a Phase I/II Study. <i>Blood</i> , 2013, 122, 3212-3212.	1.4	1
229	Dose Escalation Phase 2 Trial of Carfilzomib Combined with Thalidomide and Low-Dose Dexamethason in Newly Diagnosed, Transplant Eligible Patients with Multiple Myeloma. a Trial of the European Myeloma Network. <i>Blood</i> , 2014, 124, 2118-2118.	1.4	1
230	Prospective Molecular Monitoring of Minimal Residual Disease after Non-Myeloablative Allografting in Newly Diagnosed Multiple Myeloma. <i>Blood</i> , 2014, 124, 44-44.	1.4	1
231	Efficacy of Melflufen, a Peptidase Targeted Therapy, and Dexamethasone in an Ongoing Open-Label Phase 2a Study in Patients with Relapsed and Relapsed-Refractory Multiple Myeloma (RRMM) Including an Initial Report on Progression Free Survival. <i>Blood</i> , 2015, 126, 3029-3029.	1.4	1
232	Bortezomib and Plasma Cell Leukemia.. <i>Blood</i> , 2006, 108, 3546-3546.	1.4	1
233	Bortezomib as Front-Line Therapy in Primary Plasma Cell Leukemia. <i>Blood</i> , 2008, 112, 2784-2784.	1.4	1
234	Central Nervous System and Intracranial Myeloma: a Retrospective Italian Multicenter Study.. <i>Blood</i> , 2009, 114, 1882-1882.	1.4	1

#	ARTICLE	IF	CITATIONS
235	Outcomes for Older Patients in Stratus (MM-010), a Single-Arm, and Phase 3b Study of Pomalidomide + Low-Dose Dexamethasone in Refractory or Relapsed and Refractory Multiple Myeloma. <i>Blood</i> , 2014, 124, 4770-4770.	1.4	1
236	Proteomic Characterization of the Multiple Myeloma Bone Marrow Extracellular Matrix. <i>Blood</i> , 2014, 124, 2051-2051.	1.4	1
237	Analysis of Final Data from the Multinational, Non-Interventional, Observational Emmos Study (NCT01241396) in Patients (Pts) with Multiple Myeloma (MM) in Real-World Clinical Practice. <i>Blood</i> , 2015, 126, 3034-3034.	1.4	1
238	Minimal Residual Disease Detection By Multiparametric Flow Cytometry in Newly Diagnosed Multiple Myeloma Patients: A Preliminary Analysis of the EMN02/HO95 MM Study. <i>Blood</i> , 2015, 126, 1760-1760.	1.4	1
239	Flowcytometric Minimal Residual Disease Assessment in the EMN-02/HOVON-95 MM Trial: Used Methods and a Comparison of Their Sensitivity. <i>Blood</i> , 2016, 128, 2072-2072.	1.4	1
240	A new combination for advanced multiple myeloma. <i>Lancet Oncology</i> , The, 2011, 12, 207-208.	10.7	0
241	Latest advances in the management of elderly patients with multiple myeloma. <i>International Journal of Hematologic Oncology</i> , 2013, 2, 431-434.	1.6	0
242	IH2 INHIBITION ENHANCES PROTEASOME INHIBITOR RESPONSIVENESS IN HEMATOLOGICAL MALIGNANCIES. <i>Hematological Oncology</i> , 2019, 37, 515-515.	1.7	0
243	Impact of Early Consolidation with Bortezomib, Thalidomide and Dexamethasone on Molecularly-Detectable Disease in MM Patients in CR or VGPR Following Autologous Transplantation: Uncommon Achievement of Molecular Remission Despite Evidence of Tumor Load Reduction by Real Time PCR. <i>Blood</i> , 2006, 108, 3100-3100.	1.4	0
244	Immunoglobulin (Ig) Repertoire in Multiple Myeloma: High Frequency of Recurrent Aminoacid Substitutions in the FR2 and CDR2. <i>Blood</i> , 2006, 108, 3413-3413.	1.4	0
245	Lenalidomide Plus Dexamethasone Versus Lenalidomide Plus Melphalan and Prednisone: A Case-Control Study in Newly Diagnosed Elderly Myeloma Patients. <i>Blood</i> , 2009, 114, 2877-2877.	1.4	0
246	High Expression of mRNA and Gene Amplification of Met In Myeloma Plasma Cells Characterize a More Aggressive Disease. <i>Blood</i> , 2010, 116, 1898-1898.	1.4	0
247	IGH Repertoire Analysis In Multiple Myeloma (MM): Lack of Intra-Disease Homology and Occasional Clustering with Sequences of Other B-Cell Neoplasms Sharing Identical Geographical Origin. <i>Blood</i> , 2010, 116, 2951-2951.	1.4	0
248	Does Heparin Have An Anti-Myeloma Effect? An Analysis On Individual Data From Three Randomized Studies of GIMEMA, Nordic and Turkish Myeloma Study Groups. <i>Blood</i> , 2011, 118, 3970-3970.	1.4	0
249	Evaluation of Atypical Low Energy Fractures in Patients Affected by Multiple Myeloma Treated with Bisphosphonates. <i>Blood</i> , 2011, 118, 5134-5134.	1.4	0
250	Differences in Patterns of Treatment and Outcome Among Patients with Relapsed Refractory Myeloma From United States, Europe and Asia. <i>Blood</i> , 2011, 118, 3989-3989.	1.4	0
251	Prioritizing Content in Continuing Hematologic Oncology Education: A Survey of 51 Clinical Investigators. <i>Blood</i> , 2012, 120, 4270-4270.	1.4	0
252	miRNA in Serum and Bone Marrow Plasma Cells From Multiple Myeloma Patients. <i>Blood</i> , 2012, 120, 2921-2921.	1.4	0

#	ARTICLE	IF	CITATIONS
253	A Phase I/II Study of Bendamustine, Low-Dose Dexamethasone, and Lenalidomide (BdL) for the Treatment of Patients with Relapsed Multiple Myeloma. <i>Blood</i> , 2012, 120, 1851-1851.	1.4	0
254	Novel Agents and Autologous Stem Cell Transplantation Improve Survival of Multiple Myeloma Patients with Ages 65-70 Years: A Multicenter Retrospective Collaborative Study Between Japanese Society of Myeloma and European Myeloma Network. <i>Blood</i> , 2012, 120, 5030-5030.	1.4	0
255	Bendamustine As Salvage Therapy in Multiple Myeloma: A Retrospective, Multicenter Study From the Italian Compassionate Use Program in 78 Heavily Pre-Treated Patients.. <i>Blood</i> , 2012, 120, 2971-2971.	1.4	0
256	High Rates of Prolonged Molecular Remissions After Tandem Autologous-Nonmyeloablative Allografting in Newly Diagnosed Myeloma. <i>Blood</i> , 2012, 120, 4204-4204.	1.4	0
257	Lenalidomide (LEN)-melphalan-prednisone induction followed by LEN maintenance (MPR-R) in newly diagnosed multiple myeloma (NDMM) elderly patients (Pts) with moderate renal impairment (RI): MM-015 trial post-hoc analysis.. <i>Journal of Clinical Oncology</i> , 2013, 31, 8544-8544.	1.6	0
258	The Combination of Frailty and ISS Scores Identifies a Simple Prognostic Index for Overall Survival in Elderly Patients Treated with Novel Agents-Based Induction Therapy. <i>Blood</i> , 2014, 124, 4740-4740.	1.4	0
259	Virtual Karyotype Reconstruction By SNPs Array of Newly Diagnosed Multiple Myeloma (MM) Patients Enrolled in the EMN02 Clinical Trial. <i>Blood</i> , 2014, 124, 2033-2033.	1.4	0
260	Multicolor Flowcytometry Analysis of Hematopoietic Stem and Progenitor Cells Subsets Among Basal and Mobilized Peripheral CD34+ Cells. <i>Blood</i> , 2014, 124, 5117-5117.	1.4	0
261	Proteomic Characterization of Circulating Extracellular Vesicles Identifies Novel Serum Myeloma Associated Markers. <i>Blood</i> , 2015, 126, 1814-1814.	1.4	0
262	Significant Survival Improvement with Maintenance in Patients Achieving a Complete Response: Pooled Analysis of 4 Italian Phase III Trials in Newly Diagnosed Multiple Myeloma Patients. <i>Blood</i> , 2015, 126, 1974-1974.	1.4	0
263	Adverse event (AE) management in patients (pts) with relapsed and refractory multiple myeloma (RRMM) taking pomalidomide (POM) plus low dose-dexamethasone (LoDEX): A pooled analysis from 3 clinical trials.. <i>Journal of Clinical Oncology</i> , 2016, 34, 8031-8031.	1.6	0
264	Prolonged Follow-up Confirmed a Role for Upfront Tandem Auto-Allo Transplant in Multiple Myeloma Also in the Era of New Drugs. <i>Blood</i> , 2016, 128, 3469-3469.	1.4	0
265	An Integrated Analysis of Cardio-Vascular Adverse Events of Carfilzomib, Cyclophosphamide and Dexamethasone in Elderly Newly Diagnosed Myeloma Patients Enrolled in 3 Phase I/II Trials. <i>Blood</i> , 2016, 128, 3336-3336.	1.4	0
266	Impact of Treatment Intensification According to Patient Prognosis: A Pooled Analysis of 3 Randomized Phase III Trials. <i>Blood</i> , 2016, 128, 995-995.	1.4	0
267	Hevylite and Freelite Tests in Newly Diagnosed Multiple Myeloma: Clinical Utility and Correlations with Clinical Features. <i>Blood</i> , 2016, 128, 5625-5625.	1.4	0
268	Prognostic Implication of Somatic Mutations By Next Generation Sequencing: An Analysis from the Mmrf Compass Study in Newly Diagnosed Multiple Myeloma Patients. <i>Blood</i> , 2016, 128, 2079-2079.	1.4	0
269	Risk Stratification in Newly Diagnosed Transplant Ineligible Multiple Myeloma. , 2018, , 37-58.		0